Glucagon-receptor selective polypeptides and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11840559-B2
Application number	US-202117538507-A
Country	US
Kind code	B2
Filing date	Nov 30, 2021
Priority date	May 16, 2016
Publication date	Dec 12, 2023
Grant date	Dec 12, 2023

Abstract

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

First claim

What is claimed is:

1. An isolated polypeptide comprising the amino acid sequence:

(SEQ ID NO: 151)

X 1 SX 3 GTFTSDX 10 SKYLDX 16 X 17 X 18 AQX 21 FVX 24 WLEDEPX 31 SX 33 X 34

PPPS-OH,

or a pharmaceutically acceptable salt thereof, wherein:
X 1 =Y or W;
X 3 =H or Q;
X 10 =Y or K;
X 16 =A, S, Aib, or K;
X 17 =A, K, or Aib;
X 18 =S or R;
X 21 =E or K;
X 24 =I, Aib, or K;
X 31 =S or K;
X 33 =G or K; and
X 34 =A or S.

2. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 1 =Y.

3. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 3 =H.

4. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 10 =Y.

5. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 16 =Aib.

6. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 17 =K.

7. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 18 =R.

8. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 21 =E.

9. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 24 =Aib.

10. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 31 =S.

11. The isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 33 =G.

12. A pharmaceutical composition comprising the isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, and a suitable carrier.

13. A particle formulation comprising the isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one stabilizing component.

14. A suspension formulation comprising the particle formulation of claim 13 and a suspension vehicle.

15. An osmotic delivery device comprising the isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof.

16. The osmotic delivery device of claim 15 , further comprising:
an impermeable reservoir comprising interior and exterior surfaces and first and second open ends;
a semi-permeable membrane in sealing relationship with the first open end of the reservoir;
an osmotic engine within the reservoir and adjacent the semi-permeable membrane;
a piston adjacent the osmotic engine, wherein the piston forms a movable seal with the interior surface of the reservoir, the piston divides the reservoir into a first chamber and a second chamber, the first chamber comprising the osmotic engine;
a suspension formulation, wherein the second chamber comprises the suspension formulation and the suspension formulation is flowable and comprises the isolated polypeptide; and
a diffusion moderator inserted in the second open end of the reservoir, the diffusion moderator adjacent the suspension formulation.

17. A method of treating or alleviating a symptom of a disease or disorder associated with aberrant glucagon activity in a subject in need thereof, the method comprising administering to the subject the isolated polypeptide of claim 1 , or a pharmaceutically acceptable salt thereof.

18. The method of claim 17 , wherein the disease or disorder is type 2 diabetes mellitus.

19. The method of claim 17 , wherein the isolated polypeptide is formulated for administration by a route selected from the group consisting of parenteral, oral, transdermal, rectal, intravenous, intradermal, subdermal, subcutaneous, and any combination thereof.

Assignees

• Intarcia Therapeutics Inc
• I2O Therapeutics Inc

Inventors

• Blackwell William
• Srivastava Ved P
• Paulik Mark A
• Young Andrew
• Hunter Iii Robert Neil
• Dock Steven Thomas

Classifications

• C07K14/00

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title